UBS AM
RLAY icon

UBS AM’s Relay Therapeutics RLAY Stock Holding History

UBS AM’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.21M Buy
278,327
+67,859
+32% +$985K ﹤0.01% 1591
2026
Q1 		$2.09M Buy
210,468
+620
+0.3% +$5.55K ﹤0.01% 2021
2025
Q4 		$1.78M Buy
209,848
+7,604
+4% +$54.3K ﹤0.01% 1934
2025
Q3 		$1.06M Sell
202,244
-206,658
-51% -$788K ﹤0.01% 1987
2025
Q2 		$1.41M Buy
408,902
+107,352
+36% +$319K ﹤0.01% 2289
2025
Q1 		$790K Buy
301,550
+68,968
+30% +$270K ﹤0.01% 2396
2024
Q4 		$958K Buy
232,582
+9,293
+4% +$50.6K ﹤0.01% 2378
2024
Q3 		$1.58M Buy
223,289
+13,640
+7% +$102K ﹤0.01% 2166
2024
Q2 		$1.37M Sell
209,649
-347,647
-62% -$2.38M ﹤0.01% 2203
2024
Q1 		$4.63M Sell
557,296
-284,570
-34% -$2.78M ﹤0.01% 1285
2023
Q4 		$9.27M Sell
841,866
-23,589
-3% -$199K ﹤0.01% 1014
2023
Q3 		$7.28M Sell
865,455
-21,087
-2% -$227K ﹤0.01% 1064
2023
Q2 		$14.6M Hold
886,542
– – 0.01% 844
2023
Q1 		$14.6M Buy
886,542
+70,544
+9% +$1.26M 0.01% 844
2022
Q4 		$12.2M Sell
815,998
-13,562
-2% -$260K 0.01% 869
2022
Q3 		$18.6M Buy
829,560
+47,917
+6% +$1.05M 0.01% 779
2022
Q2 		$13.1M Buy
781,643
+207,196
+36% +$4.44M 0.01% 855
2022
Q1 		$17.2M Sell
574,447
-40,811
-7% -$990K 0.01% 881
2021
Q4 		$18.9M Buy
615,258
+381,012
+163% +$12M 0.01% 910
2021
Q3 		$7.39M Sell
234,246
-27,995
-11% -$942K ﹤0.01% 1206
2021
Q2 		$9.6M Sell
262,241
-163,210
-38% -$5.38M ﹤0.01% 1131
2021
Q1 		$14.7M Sell
425,451
-58,944
-12% -$2.56M 0.01% 957
2020
Q4 		$20.1M Buy
484,395
+229,886
+90% +$10.4M 0.01% 851
2020
Q3 		$10.8M Buy
+254,509
New +$9.7M 0.01% 925

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

UBS AM's RLAY Position: Q2 2026 in Review

UBS AM increased its Relay Therapeutics (RLAY) stake by 32% in Q2 2026, buying an estimated $985K and bringing the position to 278,327 shares worth $5.21M. The position accounts for ﹤0.01% of the portfolio, ranked #1591.

UBS AM first reported a position in RLAY in Q3 2020 and has held it in 24 quarters since. The position peaked at $20.1M in Q4 2020. 258 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • UBS AM held 278,327 shares of Relay Therapeutics worth $5.21M as of Q2 2026.
  • UBS AM bought 67,859 Relay Therapeutics shares in Q2 2026, an estimated $985K.
  • Relay Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #1591 holding.
  • UBS AM first reported a position in Relay Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • UBS AM's Relay Therapeutics position peaked at $20.1M in Q4 2020.
  • 258 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.